The Department of War is funding two studies on MDMA-assisted therapy to address PTSD in U.S. soldiers.
| PULSE POINTS |
❓ WHAT HAPPENED: The Department of War has approved two studies involving MDMA-assisted therapy for almost 200 active-duty soldiers suffering from post-traumatic stress disorder (PTSD). The upcoming trials aim to evaluate the effectiveness of MDMA in treating trauma and improving mental health among U.S. military personnel. 📺 DETAIL: The studies involve MDMA-assisted therapy for 186 active-duty soldiers suffering from PTSD. Trials are likely to take place next year and will seek to establish whether MDMA is effective at alleviating mental health problems among U.S. military personnel. Funded through the National Defense Authorization Act, which was signed in December 2023, the research is funded by with grants of $4.9m issued to Emory University and the Walter Reed National Military Medical Center. The former is working in collaboration with the University of Texas Health Science Center. The participants are scheduled to undergo three MDMA-assisted sessions over a 10-month period. It’s been confirmed that the participants will not be deployed during the 10-month period. 💬 KEY QUOTE: “Our men and women in uniform deserve every tool available to heal and stay in the fight.” – Rep. Morgan Luttrell (R-TX). 🎯 IMPACT: If successful, the studies could pave the way for MDMA-assisted therapy to become a standard medical treatment for PTSD in the military. |
Join Pulse+ to comment below, and receive exclusive e-mail analyses.